webinar recording available - register to watch

Hit discovery with self-service DNA-encoded Libraries

Since its launch four years ago, the self-service DNA Encoded Library (DEL) has been adopted by thousands of academic and industry research teams. But just as drug development has evolved with innovation, so has the DEL.

These advancements provide solutions to covalent hit discovery, hit validation, and machine learning. Please join WuXi AppTec, the pioneer in DEL technology, for this webinar to find out more about how this next-gen technology can accelerate your drug discovery.

WHO SHOULD ATTEND
  • Academics interested in screening their (protein/biomolecule) targets for drug-like chemical matter using freely accessible DELs.
  • Industry scientists interested in conducting DEL screens without revealing target identity and/or developing proprietary screening techniques in their own labs.
  • Scientists interested in protein-ligand interactions and the associated omics and machine learning research.
WHAT WILL BE LEARNED
  • Basics of how the DEL kit works
  • Introduction of next generation of DEL capabilities
  • Applications of these capabilities
watch now
watch the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Alex Satz

Alex Satz

Senior Director of DEL Strategy and Operations, WuXi AppTec HitS

Dr. Alex Satz has 16+ years of experience building and leading DNA encoded library (DEL) technology platforms, and is currently the senior director of DEL strategy and operations at WuXi AppTec. Prior to joining WuXi AppTec, Alex built and led the Roche DEL platform in Basel Switzerland and Nutley USA, and helped to develop the first industrial-scale DEL platform at Praecis Pharmaceuticals (later purchased by GlaxoSmithKline). Alex also worked as a medicinal chemist at AstraZeneca, was an NIH postdoctoral fellow at Harvard Medical School, and earned his PhD in organic chemistry from the University of California Santa Barbara. In the field of DEL, Alex has authored 18 peer-reviewed articles and two book chapters.

Wenji Su

Wenji Su

Senior Director of R&D, WuXi AppTec HitS

Dr. Wenji Su received her bachelor's and doctorate degrees in Biology from the Hong Kong University of Science and Technology and Emory University. Wenji worked at GlaxoSmithKline (GSK) R&D China and WuXi AppTec on cellular assay and screening methodologies. She is now responsible for DEL research and new technology development, as well as leading the HitS service platform in China.Dr. Wenji Su received her bachelor's and doctorate degrees in Biology from the Hong Kong University of Science and Technology and Emory University. Wenji worked at GlaxoSmithKline (GSK) R&D China and WuXi AppTec on cellular assay and screening methodologies. She is now responsible for DEL research and new technology development, as well as leading the HitS service platform in China.

Arsalan Arif
moderator

Arsalan Arif

Founder & publisher, endpoints news

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.